Skip to main content

Building Related Illness (BRI)/ Sick Building Syndrome (SBS)

BayBiotech.NET
Built environments both residential and non residential are subject to number of indoor air quality (IAQ) and Indoor environment (IE) problems that may cause acute symptoms, health risks or discomfort.
A frequent IAQ and IE investigations can determine the occurrence of BRI and provide with healthier work environment. This is of utmost importance for Pharmaceutical/ Life Sciences industry where the product is directly subject to the human usage.
Non residential buildings are more prone to BRI as there is a high volume of occupants coming from diverse geographical areas interact in an environment where the ventilation of the building is not directly under the occupants control.
Health hazard evaluation teams from the National Institute of Occupational Safety and Health (NIOSH) conducts the investigation upon request and provides with strategies to avoid the recurrence of the problem. Some of the risk factors that may be used to evaluate biological contaminants as potential causes of allergy/asthma/sinusitis are as follows:
1. Mold: active mold infestation on building material, building history of water damage, wet building site, musty odors, viable mold test results of >1000 CFU/m3 and total mold counts >10,000 S/m3.
2. Dust mites: damp interiors, > 2 ug/g mite allergen levels in floor dust samples.
3. Apart from dust mites and mold, bacterias are major contributors to indoor health hazards and some of the diseases caused due to them are Tuberculosis, Pneumonia, Diphtheria, Anthrax, Meningitis, Respiratory infections and wound infections.

Poor IAQ contributed by various identifiable factors may cause decreased work performance and may impose significant economic costs on employers. Thus, it is important to have a regular investigations planned to test the health of the buildings used for performing the work.

In the US, NIOSH has developed a protocol to serve the needs of its health hazard evaluation teams. Such a team consists of an industrial hygienist, an epidemiologist, and a technical person familiar with the operation and maintenance of building mechanical systems.

To find out more on the topic, you may want to follow the readings as under:

1. www.epa.gov
2. USEPA/ NIOSH, EPA/400/1-91/003, DHHS Publication No. 91-1141-1991.
3. Thad Godish, Indoor Environmental Quality, CRC Press LLC, 2001.

Comments

Post a Comment

Popular posts from this blog

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...
Post a Comment
Read more